Clinicopathological features of 25 patients with acquired perforating dermatosis.
BACKGROUND
Acquired perforating dermatosis (APD) is a rare group of skin disorders characterized by transepidermal elimination of dermal tissue material. There are only a few studies of APD.


OBJECTIVE
We aimed to review the clinicopathologic features of patients with APD and evaluate the outcomes of treatments.


METHODS
The medical records of 25 patients who were clinically and histopathologically diagnosed as having APD between 2006 and 2013 were retrospectively reviewed. The histopathologic sections and the results of elastic, trichrome and periodic acid Shiff (PAS) staining were evaluated.


RESULTS
Of the patients, 17 (68%) had ARPC, 7 (28%) had perforating folliculitis, 1 (4%) had Kyrle's disease. Male/female ratio was 1.3. The mean age was 51.8 ± 12.8 years. The disease duration ranged between 15 days and 96 months. Diabetes mellitus was the most common disease associated with APD (48%). The walls of vessels were PAS positive in the lesions of 6 of 13 diabetic patients. After various treatments, almost all lesions regressed in 15 (60%) patients.


CONCLUSIONS
Acquired perforating dermatosis may present with various clinical features and is mostly associated with diabetes mellitus. Diabetes mellitus may be involved in the pathogenesis of APD via microangiopathy and other mechanisms.
Dermatology Clinic.
Gulsen
G
Akoglu
Dermatology Clinic.
Selma
S
Emre
Pathology Clinic, Ankara Ataturk Training and Research Hospital, Bilkent, Ankara, Turkey.
Nuran
N
Sungu
Dermatology Clinic.
Gozde
G
Kurtoglu
Dermatology Clinic.
Ahmet
A
Metin
D000328:Adult; D000368:Aged; D001808:Blood Vessels / Q000737:chemistry; D003095:Collagen Diseases / Q000188:drug therapy / Q000473:pathology*; D003318:Corneal Opacity / Q000188:drug therapy / Q000473:pathology; D007644:Darier Disease / Q000188:drug therapy / Q000473:pathology; D048909:Diabetes Complications / Q000473:pathology; D005260:Female; D005499:Folliculitis / Q000188:drug therapy / Q000473:pathology*; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010503:Periodic Acid-Schiff Reaction; D012189:Retrospective Studies; D012867:Skin / Q000098:blood supply; D013256:Steroids / Q000008:administration & dosage
D006633:Histamine Antagonists; D013256:Steroids
clinicopathological features; perforating dermatosis